Investors & News / Media Coverage / Media Coverage Year None2020201920172016 Oct 15, 2020 Caladrius Biosciences enrolling patients in its coronavirus-induced lung damage treatment study May 15, 2020 Cell therapy improves coronary flow reserve in coronary microvascular dysfunction Jan 15, 2020 Caladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020 Dec 05, 2019 Dr. Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD Nov 21, 2019 AHA: Caladrius single injection helps heart disease that hits women the hardest Nov 21, 2019 Single-Injection Cell Therapy Relieves CMD Symptoms Nov 21, 2019 Caladrius unveils positive results of CLBS16 in CMD treatment Apr 09, 2019 Regulating Regeneration in Europe Apr 03, 2019 Caladrius Biosciences selected as BioNJ’s Emerging Company in the Spotlight Mar 08, 2019 FutureTech Podcast featuring Douglas W. Losordo, MD, FACC, FAHA, Executive Vice President, Global Head of Research and Development, Caladrius Biosciences – Cells, Tissue, and Repair Pagination Current page 1 Page 2 Next page next › Last page last » Print Page RSS Feeds Email Alerts
Year None2020201920172016 Oct 15, 2020 Caladrius Biosciences enrolling patients in its coronavirus-induced lung damage treatment study May 15, 2020 Cell therapy improves coronary flow reserve in coronary microvascular dysfunction Jan 15, 2020 Caladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020 Dec 05, 2019 Dr. Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD Nov 21, 2019 AHA: Caladrius single injection helps heart disease that hits women the hardest Nov 21, 2019 Single-Injection Cell Therapy Relieves CMD Symptoms Nov 21, 2019 Caladrius unveils positive results of CLBS16 in CMD treatment Apr 09, 2019 Regulating Regeneration in Europe Apr 03, 2019 Caladrius Biosciences selected as BioNJ’s Emerging Company in the Spotlight Mar 08, 2019 FutureTech Podcast featuring Douglas W. Losordo, MD, FACC, FAHA, Executive Vice President, Global Head of Research and Development, Caladrius Biosciences – Cells, Tissue, and Repair Pagination Current page 1 Page 2 Next page next › Last page last »
Oct 15, 2020 Caladrius Biosciences enrolling patients in its coronavirus-induced lung damage treatment study
Jan 15, 2020 Caladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020
Dec 05, 2019 Dr. Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD
Mar 08, 2019 FutureTech Podcast featuring Douglas W. Losordo, MD, FACC, FAHA, Executive Vice President, Global Head of Research and Development, Caladrius Biosciences – Cells, Tissue, and Repair
